Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript

Poolbeg Pharma PLC ( POLBF ) Shareholder/Analyst Call September 24, 2026 9:00 AM EDT Company Participants Jeremy Skillington - CEO & Director Liam Tremble - Principal Scientist Ian O'Connell - CFO & Director Presentation Operator Good afternoon, and welcome to the Poolbeg Pharma plc Investor Presentation. [Operator Instructions] Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Jeremy Skillington, CEO. Good afternoon, sir. Jeremy Skillington CEO & Director Good afternoon, and thank you for the introduction. And thank you, everybody, for joining us this afternoon for the Poolbeg presentation, of course, on the back of our RNS this morning talking about the interim results. Again, we have a fantastic presentation to go through to kind of update you on that. I'm delighted to be joined by my colleagues, Liam Tremble and Ian O'Connell, and we'll kick off, and let's go through this. So as I say, we're -- we've got the team with us today. I'll talk about the background, talk about the company to kind of set the scene. Liam will talk more about the clinical trial, the TOPICAL clinical trial, I'd say we've kind of announced the positive interim data this morning. We're all delighted with that just as things are moving. We've got some terrific momentum now. So we're looking to kind of execute. And then Ian will speak more about the commercial opportunity that we have here because ultimately, we're looking for partners and partner the program. So we'll talk a little bit about that. So again, to set the scene, Poolbeg Pharma, clinical stage company. We're developing POLB 001 to potentially transform the lives of cancer patients to allow them to have their cancer immunotherapy treatment safe and locally. And by doing that, we're preventing CRS is the plan. That's our goal to prevent Cytokine Release